Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

New Research Finds Severity of COVID-19 Does Not Differ According to Trimester

Society for Maternal-Fetal Medicine

Research shows that pregnant people who contract COVID-19 are at increased risk of severe complications, including hospitalization, ventilation, and death, compared to pregnant people without COVID-19. However, little is known about how the timing of COVID-19 infection during pregnancy might impact a pregnant person’s risk of developing severe symptoms. In a new study to be presented today at the Society for Maternal-Fetal Medicine’s (SMFM) annual meeting, The Pregnancy Meeting™, which is being held virtually, researchers will unveil findings that suggest that the severity of COVID-19 does not differ by trimester. “Regardless of what trimester they are in, pregnant people are at risk of developing severe COVID illness,” said one of the study’s authors, Rachel Schell, MD, a maternal-fetal medicine fellow at the University of Texas Southwestern Medical Center in Dallas. Researchers identified a group of pregnant people at a single urban hospital in Dallas, Parkland Hospital, and followed the progression of their COVID-19 symptoms. From March 18, 2020 to May 31, 2021, 1,092 pregnant people were diagnosed with COVID-19. Sixty-seven people (6 percent) were diagnosed in the first trimester, 309 (28 percent) in the second trimester, and 716 (66 percent) in the third trimester. There were no significant demographic differences between the groups. Across all trimesters, 993 out of 1092 people (90.9 percent) were either asymptomatic or had mild COVID-19 symptoms, and 35 out of 345 people (10.1 percent) who were initially asymptomatic developed moderate, severe, or critical symptoms. Among pregnant patients who were initially asymptomatic or had mild symptoms in any trimester, 5 percent developed moderate, severe, or critical illness. “This research is helpful for us in counseling patients who test positive for COVID,” said another one of the study’s authors, Emily Adhikari, MD, a maternal-fetal medicine subspecialist at the University of Texas Southwestern Medical Center and medical director of perinatal infectious diseases at Parkland Hospital. “There is no reason to be hesitant to get vaccinated because you are early in your pregnancy. You’re still at risk of getting really sick from COVID in your first trimester.” Researchers are in the process of expanding their research to look at whether there are significant differences or changes in COVID severity by trimester due to the Delta variant. SMFM, the Centers for Disease Control and Prevention (CDC), and the American College of Obstetricians and Gynecologists recommend all pregnant people get vaccinated against COVID-19, noting that the vaccines are safe and effective. Vaccination rates among pregnant people continue to remain low despite evidence showing vaccines can help to prevent severe illness during pregnancy. The latest figures from the CDC show that fewer than 36 percent of pregnant people are vaccinated; vaccination rates are even lower among pregnant people who are Black and Hispanic. The abstract has been published in the January 2022 supplement of the American Journal of Obstetrics and Gynecology (AJOG ) and can be accessed at no cost on the AJOG website. To view the presentation of this abstract or other Pregnancy Meeting™ abstracts and events, visit the SMFM website or contact Karen Addis at karen@addispr.com or 301-787-2394. ### The Society for Maternal-Fetal Medicine (SMFM), founded in 1977, is the medical professional society for obstetricians who have additional training in high-risk, complicated pregnancies. SMFM represents more than 5,000 members who care for high-risk pregnant people and provides education, promotes research, and engages in advocacy to reduce disparities and optimize the health of high-risk pregnant people and their families. SMFM and its members are dedicated to optimizing maternal and fetal outcomes and assuring medically appropriate treatment options are available to all patients. For more information, visit SMFM.org and connect with the organization on Facebook and Twitter. For the latest 2022 Annual Meeting news and updates, follow the hashtag #smfm22. EMBARGOED FOR RELEASE: Feb. 3, 2022 9:00 a.m. EST Contact Details Karen Addis +1 301-787-2394 KAREN@ADDISPR.COM Company Website https://www.smfm.org/

February 03, 2022 09:00 AM Eastern Standard Time

COVID-19 Dream Body: Gio Nation Goes In-Depth About The Pandemic & The Mental Effects Of Quarantine

Gio Nation

The COVID-19 outbreak spread worldwide at an alarming rate as 2019 ended. By 2020, the world itself came to a grinding halt. Every industry sustained heavy losses as production stopped and people went under lockdown. While everyone is staying at home to weather this pandemic, the fantastic American singer-songwriter, Gio Nation, talks about how he was able to use all of his free time to let his creativity flourish. Even if quarantined, Gio explains that it doesn’t mean one can’t grow and learn from this experience. For Gio the pandemic was an opportunity to hone his craft, develop new skills, & improve his mental health. Gio admits he also became obsessed with physical fitness. Plunging himself into HIT training & achieving the body he's always dreamt of having. “ We finally have the chance to sit with ourselves without all the usual manic minutiae of living in the 2020’s,” Gio Nation says, “ We have an abundance of time & an abundance of knowledge at our fingertips!” Every creative person needs two things to work on their craft, time and a distraction-free environment. This lockdown offers up that chance on a silver platter. Gio Nation also encourages all to use this time to their advantage as well as focus on both their physical & mental health during this time. “ I feel like Bradley Cooper in Limitless in the pandemic. It’s like I took that pill, and I now have the mental space and freedom to create and make music; it's what I love to do. My creativity has gone through the roof because what else are you gonna do? Binge-watch Netflix? You've already done that for 12 hours!” – Gio Nation. COVID-19 has given us a fresh perspective on the ways of the world. Every artist got hit hard when all the venues, concerts, and bars closed since nobody had a platform to perform anymore. Gio Nation shares how he went from having too many gigs to handle to none at all. That’s why in this digital age having a solid social media presence is good for business. Many things can be achieved through the genius of technology. Working from home, online concerts, online shopping, online classes, online medical care, and that’s just the tip of the iceberg; it is simply astounding. “ The internet is the new frontier. It's been the new frontier, but I think people finally get it. You can spread art like a virus, and it can reach every pocket of the world. We knew that before but now we really know it. The digital platform is the frontier.” replied Gio Nation when asked what lessons will be learned from the COVID mess in the music industry. With an idealistic point of view of the world, Gio’s biggest dream is to eliminate all the negative thoughts and spread love and positivity. He dreams of inspiring people through his music and guiding them on how they can use their creative juices to make the most out of their lives. Gio Nation is a rising singer-songwriter, producer, and a thrilling performer from America, strongly influenced by pop culture. Hailing from a lower-middle-class family in Connecticut, Gio found his vocation in writing and performing at 7 years old, then found a flair for writing songs. His journey through depression, substance abuse, and even homelessness has given him a positive outlook on life that shows in his vibrant and ebullient personality. Contact Details Gio Nation +1 804-305-5501 gionationempire@gmail.com 360PRWire Dominic Jonas +1 618-328-3245 dom@360prwire.com Company Website https://gionationempire.com/

February 02, 2022 01:46 PM Eastern Standard Time

Image

Reaxys to enhance chemistry patents with patent provenance for greater competitive intelligence insights

Elsevier

Elsevier, a global leader in research publishing and information analytics, is pleased to announce its market leading position in chemistry patent coverage and the extension of its collaboration with LexisNexis® PatentSight®. In March 2021, Elsevier launched its initiative to strengthen the existing patent coverage in Reaxys ®. The content expansion resulted in a 15-fold increase in patent coverage and ensures pharma and chemical companies and their researchers do not miss key competitive intelligence insights. The number of discoverable patents in Reaxys now exceeds 30 million, and the Reaxys-PatentSight collaboration will further enhance content with the patents’ ownership information. These insights will enable companies to better understand competitors’ IP strategies, identify innovative players in a field and confidently assess the commercial viability of their projects. Marco Richter, Global Head of Product, LexisNexis Intellectual Property Solutions, said: “Competition is intense in R&D: With an increasingly diverse landscape of players in the pharmaceutical industry — from niche start-ups to emerging biotech companies, to academic research. To strengthen drug discovery capabilities and shorten development cycle, pharma companies often acquire specialized biotech companies or in-license drug candidates active in preclinical and clinical phases. “Keeping up with the latest information about competitor IP activity and new research is a business-critical challenge. We are pleased to be continuing our collaboration with Elsevier to provide companies with more extensive information on IP history and understand that getting new drugs to market is a resource-intensive process for researchers and know our content can help accelerate this.” The Reaxys updates will enhance competitive intelligence by distinguishing “current patent assignee” and “original patent assignee” to track ownership over time, demonstrating which companies are most prominent in a particular field. Easy-to-use search filters will allow users to sort between inventors and current patent holders. Further enhancements to the patent assignee ontology that unify different common and legal names for corporations will be released in 2022. This allows companies to avoid blind spots and stay on top of emerging competitors when assessing the competitive landscape for a technology. Dr. Ivan Krstic, Head of Chemistry Solutions at Elsevier added: “Reaxys users want to clearly view current and past patent holders. These upgrades are in response to their feedback, and underlines our commitment to addressing user needs and responding in a timely manner with significant enhancements to the content and user experience. Because of this virtuous cycle, Reaxys has become the patent discovery space for chemists in pharma and chemical companies. “This work underpins our vision to make Reaxys the most comprehensive, innovative and authoritative chemistry research information system that supports chemistry workflows and use cases, enabling the digital transformation that organizations need to achieve to help drive better research outcomes.” To find out more about the collaboration and patent coverage in Reaxys, visit the Reaxys website. --- About LexisNexis Legal & Professional LexisNexis® Legal & Professional is a leading global provider of legal, regulatory and business information and analytics that help customers increase productivity, improve decision-making and outcomes, and advance the rule of law around the world. As a digital pioneer, the company was the first to bring legal and business information online with its Lexis ® and Nexis ® services. LexisNexis Legal & Professional, which serves customers in more than 150 countries with 10,600 employees worldwide, is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. About LexisNexis Intellectual Property LexisNexis Intellectual Property brings clarity to innovation for businesses worldwide. We enable innovators to accomplish more by helping them make informed decisions, be more productive, comply with regulations and ultimately achieve a competitive advantage for their business. Our suite of workflow and analytics solutions (LexisNexis ® IP Data Direct, LexisNexis PatentAdvisor ®, LexisNexis PatentOptimizer ®, LexisNexis ® PatentSight ® and LexisNexis TotalPatent One ® ) enables companies to be more efficient and effective at bringing meaningful innovations to our world. We are proud to directly support and serve these innovators in their endeavors to better humankind. About Elsevier As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems. In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, health professionals, institutions and funders. Elsevier employs 8,100 people worldwide. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, Reaxys, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, and health education. Researchers and healthcare professionals rely on our 2,500+ digitized journals, including The Lancet and Cell; our 40,000 eBook titles; and our iconic reference works, such as Gray's Anatomy. With the Elsevier Foundation and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world. Elsevier and LexisNexis are part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. Contact Details David Tucker Elsevier Communications, UK d.tucker@elsevier.com Company Website https://www.elsevier.com/

February 02, 2022 09:00 AM Eastern Standard Time

How to improve medication safety for inpatient children and infants reported in PATIENT SAFETY

Patient Safety Authority

Recognizing the importance of pharmacists and their crucial role in our health and well-being, the Patient Safety Authority (PSA) has published a special issue of PATIENT SAFETY dedicated to pharmacy education and practice. In it, a team from the Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University write about why children and babies are uniquely vulnerable to medication errors in the hospital and how to keep them safe. A survey of children’s hospitals found that only 2/3 of them had a medication safety pharmacist. The diversity of the patient population, rapid changes in the weight of newborns, and the use of specialized compounds makes the medication dispensing process particularly challenging among children and babies. Advances in patient safety like standardizing extemporaneous medication preparation, computerized physician order entry (CPOE) systems, and specialized systems to reduce the administration of medications by the incorrect route can help to make the medication-use system safer, according to the authors. “The increased risk of medication errors in pediatric and neonatal patients and inconsistent medication safety resources in institutions underscore the importance that all clinicians play an active role in strengthening medication-use system safety,” writes assistant professor of pharmacy practice Kyle Hampson. The special issue of PATIENT SAFETY honors the important role of pharmacists in dealing with COVID-19 and in stewarding patient safety in medication management. “Despite the challenges of the pandemic, many healthcare professionals still see the good, they still have hope, and they want to continue making a difference. Pharmacists are some of these people. They continue to demonstrate the meaning of teamwork as they keep showing up to help us overcome one of the biggest public health challenges of our lifetime,” says Regina Hoffman, executive director of the PSA. Other topics in this issue of PATIENT SAFETY include: Mitigating vaccine patient fears and anxiety – Mass vaccination efforts for COVID-19 have increased the number of immunization stress-related reactions (ISRR). University of Pittsburgh School of Pharmacy senior scholars discuss administration protocols including patient screening, observation, and reporting to minimize the potential for vaccine-related adverse events. Antibiotic stewardship opportunities in the ER – Every year, thousands of emergency department (ED) visits result in patients being discharged with oral antibiotic prescriptions but studies that assess the appropriateness of antibiotic regimens are limited. A study by pharmacists at the Veterans Affairs Medical Center and Saint Vincent Hospital in Erie, PA found that of the non-optimal antibiotic regimens, most had an excessive duration. Targeted local education efforts and future clinical decision support can facilitate appropriate prescribing. PATIENT SAFETY is the peer-reviewed journal of the Patient Safety Authority. A scientific publication, PATIENT SAFETY humanizes patient harm with stories, opinion pieces, and magazine-quality design. It has a readership of more than 45,000 people in 164 countries. About PSA Established under the Medical Care Availability and Reduction of Error (MCARE) Act of 2002, the PSA, an independent state agency, collects and analyzes patient safety data to improve safety outcomes and help prevent patient harm. http://patientsafety.pa.gov/ Contact Details Bev Volpe +1 609-230-4696 bev@madisongall.com Company Website http://patientsafety.pa.gov/

February 01, 2022 01:40 PM Eastern Standard Time

Image

Kramer acquires UC Workspace in strategic move to expand the boundaries of collaboration

Kramer Electronics

Kramer Electronics Ltd. announced today the acquisition of UC Workspace (UCW), a pioneer and leader in unifying collaborative experiences. Uniting UCW’s and Kramer’s technology and product portfolios under one roof creates new and unique opportunities to bring a new level of simplicity, automation and collaboration to Enterprise and Education customers. UCW products facilitate engagement across multiple platforms, providing intuitive ways to communicate, control and collaborate. Its award-winning Quicklaunch software solution enables people and organizations to seamlessly engage across multiple UCC platforms. It is the fastest and most secure and intuitive way to launch and control any meeting regardless of conferencing provider. With its upcoming WEAV content and interaction platform and UCCentral software, which provides unparalleled insight and control of workspaces, devices and apps, UCW innovation is helping organizations boost productivity across multiple dimensions. “This acquisition is the latest step in our journey to reinvent the collaboration experience,” said Gilad Yron, Kramer’s CEO. “It is a power-up in our commitment to creating new ways for people to engage and collaborate more intuitively, simply and inclusively, and with that, to bring more layers of productivity to our customers.” He continued: “Bringing UCW into the Kramer family accelerates our drive to build a market-leading product and R&D organization. It’s a perfect fit with our existing technologies and our innovation plans for the new physical-digital world.” Angela Hlavka, CEO of UC Workspace, said: “Having created the market for unified collaborative experiences, we are thrilled to take UCW technology and partner network to a new scale. This will benefit all our customers, through a broader range of solutions, new technologies and market-leading customer support. We are delighted to join the Kramer family on this exciting journey toward better and more productive collaboration for all.” About Kramer We’re dedicated to delivering better, smarter solutions that enhance physical-digital engagement and collaboration. Kramer solutions are based on our cutting-edge products and technologies for traditional AV, AV over IP, unified communication and collaboration (UCC) and wireless collaboration, and advanced management and control. www.kramerav.com About UCW UC Workspace is a leading global provider of unified collaboration solutions, helping companies move beyond traditional meeting rooms to inspiring workspaces that improve collaboration, sharing, communication and technology integrations. UC Workplace works with multiple meeting providers and are agnostic to applications and hardware. Platinum Partners have optimized customized versions of our flagship Quicklaunch application. www.ucworkspace.com Contact Details Ornit Sade Benkin +972 52-332-7700 osade@kramerav.com Company Website https://www.kramerav.com/

February 01, 2022 12:00 PM Eastern Standard Time

Move Beyond Trauma and Chronic Pain with the Mind-Body Connection

River Grove Books

Chronic pain takes an immense physical toll on the body, affecting all aspects of daily life. The symptoms, when coupled with the uncertainties of misdiagnoses and ineffective treatments, create a world of fear and anguish. In My Pain-Body Solution: A Journey to the Other Side of Suffering (River Grove Books), Michael J. Murray chronicles his difficult battle to conquer undiagnosed pain. Murray confides his emotional torment and near collapse as numerous doctors—most of whom don’t actually take the time to truly listen to their desperate patient—promise relief but only deliver ineffective treatments, contradicting diagnoses, and often dispassionate care. In the end, Murray’s chance discovery in a book on back pain leads to a dawning awareness of the emotional root of his near-constant agony. Interspersed with spirited vignettes that reflect on the beauty of nature and Murray’s love of the outdoorsman’s life, the book follows Murray as he digs deeper into the medical and therapeutic disciplines connecting the mind and body. In an accessible and engaging layman’s voice, Murray uncovers and explains how seemingly benign experiences from his past manifest as physical and emotional pains in his present. “If you are suffering from pain and looking for answers, Mike Murray’s book, My Pain-Body Solution, is a must read,” says Brendan Carney of Acupuncture North. “We are lacking patient-centered stories about pain that offer valuable information. This book is both an excellent resource on the current state of mind-body medicine and a trail map for those suffering from unexplained chronic pain.” Murray’s recounting of his journey is honest and vulnerable, and anyone who is suffering from chronic physical or emotional pain or knows someone on this difficult path will appreciate his insights on the deep connection between mind and body; the inspiring, innovative methods that can cure physical and emotional pain; and how to heal our inner selves to heal physical pain. “I wrote this book while I was in extreme pain, both physically and, as it turned out, emotionally,” Murray said. “I’ve learned many lessons along the way. It is my hope that you will be inspired by the teachings I have received. My wish is that this impacts you and those around you in a positive way.” “Michael J. Murray points you toward understanding pain, its personal message, and its ultimate relief,” said Tina Welling, author of Writing Wild: Forming a Creative Partnership with Nature. “Murray’s story is riveting, and it’s your story as well. His persistence in tracking down the truth and the inspiring self-awareness that resulted will set you on your own path to a new relationship with your body. My Pain-Body Solution is an enjoyable read while serving as a guide to living more fully.” This eye-opening memoir is an excellent guide for anyone who wants to truly feel better and enjoy a heightened sense of well-being. Pick up your copy of My Pain-Body Solution today and keep up with Michael Murray’s latest endeavors by visiting mypainbodysolution.com. About the Author Michael James Murray was born and grew up in Sudbury, MA. After graduating college in 1988, he spent the following year living as a ski bum in Aspen, Colorado. Upon returning from the Rockies, he moved to New Hampshire. In 2007, at the age of forty-three, he retired after he and his two business partners built and sold a successful financial services business. He lives in North Hampton, New Hampshire, is married, and has three grown children. He is an avid outdoorsman and loves to backcountry ski, fly-fish, hike, cycle, and surf. He has a second home in Wilson, Wyoming at the base of the Tetons where he resides part of the year, pursuing his passions. My Pain-Body Solution is Michael Murray’s first book. # # # More about Greenleaf Book Group Greenleaf Book Group is an independent publisher and distributor located in Austin, Texas, dedicated to empowering authors. Greenleaf’s hybrid publishing model is uniquely positioned to offer the benefits of both traditional publishing and self-publishing. To learn more about Greenleaf, visit www.greenleafbookgroup.com. Contact Details Greenleaf Book Group Sam Ofman +1 512-891-6100 media@greenleafbookgroup.com

February 01, 2022 10:10 AM Central Standard Time

Image

G Medical Innovations Holdings Ltd Announces $12 Million Private Placement

G Medical Innovations Holdings

G Medical Innovations Holdings Ltd. (NASDAQ:GMVD) (the "Company"), a telehealth, medical device, and remote patient monitoring company providing clinical-grade solutions for consumers, medical professionals, and healthcare institutions, today announced it has entered into a securities purchase agreement with a single institutional investor to issue, in a private placement, 2,400,000 ordinary shares (or pre-funded warrants in lieu thereof) and warrants to purchase up to an aggregate of 2,400,000 ordinary shares, at a purchase price of $5.00 per ordinary share (or pre-funded warrant) and associated warrant, for expected gross proceeds to the Company of approximately $12 million, before deducting placement agent fees and other offering expenses payable by the Company. The warrants will have an exercise price of $5.00 per ordinary share, will be exercisable immediately upon issuance, and will have a term of five years from the date of issuance. The closing of the private placement is expected to occur on or about February 2, 2022 subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the private placement for partial repayment of existing debt and working capital purposes. A.G.P./Alliance Global Partners is acting as the sole placement agent for the private placement. The offer and sale of the foregoing securities are being made in a transaction not involving a public offering and the securities have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. Under an agreement with the investors, the Company agreed to file a registration statement with the Securities and Exchange Commission (the "SEC") covering the resale of the ordinary shares to be issued to the investors (including the ordinary shares issuable upon the exercise of the warrants) no later than 15 days after the closing and to use commercially reasonable efforts to have the registration statement declared effective as promptly as practical thereafter, and in any event no later than 60 days in the event of a "full review" by the SEC. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About G Medical Innovations G Medical Innovations Holdings Ltd. is an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms. The Company’s solutions and services can empower consumers, patients, and providers to better monitor, manage and improve clinical and personal health outcomes, especially for those who suffer from cardiovascular disease (or CVD), pulmonary disease and diabetes. The Company’s current product lines consist of its Prizma medical device (or Prizma), a clinical grade device that can transform almost any smartphone into a medical monitoring device enabling both healthcare providers and individuals to monitor, manage and share a wide range of vital signs and biometric indicators; its Extended Holter Patch System, a multi-channel patient-worn biosensor that captures electrocardiography (or ECG) data continuously, including its QT Syndrome Prolongation Detection Capabilities Patch. In addition, the Company is developing its Wireless Vital Signs Monitoring System (or VSMS), which is expected to provide full, continuous, and real time monitoring of a wide range of vital signs and biometrics. Its monitoring services include provision of Independent Diagnostic Testing Facility (or IDTF) monitoring services and private monitoring services. Visit https://gmedinnovations.com/. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, G Medical is using forward-looking statements when it discusses the closing of the private placement and the expected use of proceeds. Because such statements deal with future events and are based on G Medical’s current expectations, they are subject to various risks and uncertainties, and actual results, performance, or achievements of G Medical could differ materially from those described in or implied by the statements in this press release. The forward looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in G Medical’s prospectus filed pursuant to Rule 424(b)(4), filed with the Securities and Exchange Commission (“SEC”) on June 28, 2021, and in any subsequent filings with the SEC. Except as otherwise required by law, the companies undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. G Medical and McDade Products are not responsible for the contents of third-party websites. INVESTOR RELATIONS CONTACT: G Medical Innovations Kobi Ben-Efraim, CFO +972 8-958-4777 service@gmedinnovations.com Contact Details Kobi Ben-Efraim, CFO +972 8-958-4777 service@gmedinnovations.com Company Website https://gmedinnovations.com/

January 31, 2022 07:00 AM Eastern Standard Time

BitX Funding Triumphs With Record 2021 Results

BitX Funding

Fairfield, CT., January 24, 2022— BitX Funding, one of the most prominent alternative lenders in Southern Connecticut, announced a banner year for growth in 2021. Overall, revenue went up 10%, new users increased by 70%, impressions went up 300%, and business applications came in at a rate of 1,275% more than the previous year. Out of all the loans that BitX sold, Startup loans had the highest increase. “Our economy saw solid growth in small business lending and the startup loan category lead the way due to the great resignation”, said Todd Rowe, president of BitX Funding. “We continue to grow BitX revenue with support from internal sales, record marketing results, CT Innovations mentor support, and our raving fans. Our 2022 goals are to continue to build out our lending platform, grow our lender base, obtain our own lending facility, and drive client growth. Our goals are to increase revenue by 160%, have a 133% increase in units sold, and a loan amount increase of 200% in 2022.” Rowe continues to promote his company as a marketplace for small business loans, especially with young entrepreneurs. With one click, you can get a response to your loan request within 24 hours. That makes BitX Funding a partner you can trust in 2022. BitX Funding is an omnichannel marketplace for alternative small business loans and business insurance. BitX connects their clients with the right loan and lender from SBA 7a, start-up loans, short-term loans, mid-term loans to merchant cash advances and business lines of credit. BitX is where lenders compete for your business. Our top-rated lenders focus on real-life business data and cash flow, which means you can qualify for small business loans even if your credit score isn’t perfect. We care about small business and it’s our mission to secure the right funding when you need alternative small business loans within our small business loan marketplace. Contact Details BitX Funding Todd Rowe +1 203-763-1430 info@bitxfunding.com Company Website https://www.bitxfunding.com

January 27, 2022 01:05 PM Eastern Standard Time

2021 In Numbers: Mass. Cannabis Industry Testing Statistics

MCR Labs

Following another year of unpredictability, change, and challenges for the Massachusetts cannabis industry, MCR Labs is releasing data that may provide insight into the industry’s continued development. Here are MCR Labs’ most notable stats from Jan. 1, 2021 to Jan. 2, 2022: The Lab saw a 19% increase in samples submitted for testing, in comparison to 2020’s 38% increase. While flower sample submissions decreased by 8%, concentrate and vape submissions grew by 22%. The decrease in flower samples can be reasonably attributed to a regulatory change in batch size enacted in March. Solventless extract sample submission increased by 85%, and can most likely be attributed to the rising popularity of Hash Rosin. Hash Rosin submissions increased by 700%. Samples submitted to MCR in 2021 had a 92.3% pass rate for safety screens, up from 91.2% in 2020. For concentrate and vape samples, the pass rate decreased from 93.5% in 2020 to 91.8% in 2021, which can be attributed mostly to an increase in residual solvent failures. “As more and more facilities come online and employ hydrocarbon extraction techniques, we expect failures to remain the same or increase due to the extremely low regulatory limits,” said Jonathan Wani, Vice President of Business Development at MCR Labs. MCR Labs is licensed as an independent testing laboratory in both the Medical and Adult Use Marijuana programs, both overseen by the Massachusetts Cannabis Control Commission (CCC). The statistics provided here account for product samples submitted for compliance testing by cultivators and product manufacturers from the medical and adult-use programs, as well as home growers, patients, researchers, or curious consumers. About MCR Labs: MCR Labs is one of the longest operational cannabis testing laboratories on the East coast with facilities operating in several legal cannabis markets. We are ISO/IEC 17025:2017 accredited providers of analytical cannabis product testing and R&D services committed to assisting licensed marijuana establishments, patients, researchers, entrepreneurs, and advocates. Our team of chemists and pharmaceutical scientists are dedicated to advancing public health and safety through leading-edge chemical analysis of cannabis products and offering unparalleled guidance and support for partners, regulators, and the communities we serve. For more information visit http://mcrlabs.com. Contact Details MCR Labs Alexandra Gomes +1 508-782-9772 alexandra@mcrlabs.com Company Website http://mcrlabs.com

January 27, 2022 09:00 AM Eastern Standard Time

1 ... 243 244 245 246 247 ... 311